Adamis Pharmaceuticals

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

SAN DIEGO, Oct.  08, 2019  (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) (“Adamis”) announced today the presentation of data pertaining to its investigational high dose naloxone product (ZIMHI) at the Institute of Human Virology (IHV) meeting (http://www.ihv.org/ihvmeeting/Program/) in a session on “Opioid Intersection”. Other participants at the meeting included Dr. Robert Gallo, Co-Founder and Director, Institute of Human Virology, Dr. Nora Volkow, Director, National Institute of Drug Abuse, National Institutes of Health, and Admiral Brett Giroir, MD, Assistant Secretary for Health, US Department of Health and Human Services. The Adamis data was presented by Dr. Ronald Moss, Chief Medical Officer at Adamis.

Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting

Adamis recently secured a Australian and New Zealand partnership for SYMJEPI. Although this was a positive move for the company, the market responded negatively with a new 52-week low.

Adamis-Emerge Partnership Displeases Investors

SAN DIEGO, Oct.  01, 2019  (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty (“Emerge”) to register and commercialize Adamis’ SYMJEPI® (epinephrine) Injection products in Australia and New Zealand.

Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand

Adamis recently updated investors on the progress made in the launch of SYMJEPI and SYMJEPI Jr. Unfortunately, the market wasn't impressed and the stock hit another 52-week low.

Adamis Updates Investors On SYMJEPI Launch And ZIMHI PK Study, While The Stock Hits A New 52-Week Low

SAN DIEGO, Aug.  28, 2019  (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPITM (epinephrine) 0.3 mg and 0.15 mg Injections.

Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI

SAN DIEGO, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors.

Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors

Adamis recently reported a mixed Q2 earnings with a beat on EPS and a miss on revenue. I review the earnings report and the company's conference call.

Adamis: Past Hurdles Could Lead To A Successful Future

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q2 2019 Results - Earnings Call Transcript

Adamis has settled their patent and trademark legal battles with kaléo Inc. Now, Adamis can focus on finding a commercial partner for their ZIMHI product candidate before the October PDUFA.

Adamis Settles Legal Disputes Ahead Of ZIMHI PDUFA

Novartis

Sandoz recently announced the U.S.retail launch of SYMJEPI in the middle of a Epipen shortage around the country.

Sandoz And Adamis Pharmaceuticals Will Benefit From Epipen Shortage

Adamis has been a tortuous investment for most shareholders due to a never-ending devaluation of their investment. However, it appears the market has created a deep discount.

Adamis: Share Price Continues To Grind Down To A Fine Discount

Adamis recently announced their Q1 earnings and reported a slight miss on EPS and revenue. However, it was the company's announcement that they cut Op-Ex in order to prevent an offering.

Adamis: Cuts Op-Ex And Prepares For 'Zimhi' Approval

Adamis Pharmaceuticals' (ADMP) CEO Dennis Carlo on Q1 2019 Results - Earnings Call Transcript

Adamis (ADMP) delivered earnings and revenue surprises of -11.76% and -17.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Adamis' share price roller coaster marches forward as commercialization of Symjepi provides support.

News for Adamis Pharmaceuticals Stock (ADMP)